Analysts broadly trimmed their valuations and target prices for F&P – now ranging between $24 and $30 – but held onto a positive view of the stock in the long term.
Jarden upgraded the stock from ‘neutral’ to ‘overweight’ now that the share price had corrected due to the inevitable fall in revenue that comes with fewer hospitalisations.
Analyst Adrian Allbon said he was still confident in the stock’s longer-term growth as it had placed lots of hardware in hospitals during the pandemic.
With recent falls comes some upgrades too ....Jarden upgrading to overweight should carry some weight ...